Payment overview · 2025
General Payments
$290.49
11 reported records · 2 companies
Healthcare provider profile · identity verified
Jorge Valdesuso, MD
Allopathic & Osteopathic Physicians|General Practice · SANJUAN, PR · NPI 1801830427
Verified facts
What the public records show
CMS Open Payments records show Jorge Valdesuso, MD received $290.49 in general payments during 2025 across 11 reported records.
BioCryst US Sales Co., LLC accounted for 61.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $177.74 | 61.2% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.75 | 38.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $290.49 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $177.74 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $112.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 209 |
| Metformin Hcl | Metformin Hcl | 563 | 178 |
| Gabapentin | Gabapentin | 557 | 183 |
| Losartan Potassium | Losartan Potassium | 519 | 192 |
| Pantoprazole Sodium | Pantoprazole Sodium | 505 | 140 |
| Temazepam | Temazepam | 488 | 78 |
| Simvastatin | Simvastatin | 466 | 165 |
| Famotidine | Famotidine | 430 | 148 |
| Diclofenac Potassium | Diclofenac Potassium | 416 | 184 |
| Synthroid | Levothyroxine Sodium | 412 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 359 | 130 |
| Clonazepam | Clonazepam | 333 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 305 | 104 |
| Omeprazole | Omeprazole | 295 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 278 | 106 |
| Methylprednisolone | Methylprednisolone | 258 | 151 |
| Azithromycin | Azithromycin | 238 | 188 |
| Lisinopril | Lisinopril | 237 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 94 |
| Sertraline Hcl | Sertraline Hcl | 170 | 54 |
| Dexamethasone | Dexamethasone | 163 | 132 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 162 | 104 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 125 |
| Glimepiride | Glimepiride | 153 | 49 |
| Alendronate Sodium | Alendronate Sodium | 151 | 55 |
| Irbesartan | Irbesartan | 140 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 140 | 47 |
| Montelukast Sodium | Montelukast Sodium | 136 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 51 |
| Alprazolam | Alprazolam | 123 | 25 |
| Glipizide | Glipizide | 113 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 112 | 97 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 40 |
| Indapamide | Indapamide | 105 | 41 |
| Meloxicam | Meloxicam | 102 | 44 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 100 | 24 |
| Memantine Hcl | Memantine Hcl | 96 | 40 |
| Enalapril Maleate | Enalapril Maleate | 95 | 26 |
| Buspirone Hcl | Buspirone Hcl | 94 | 38 |
| Sucralfate | Sucralfate | 90 | 29 |
| Lorazepam | Lorazepam | 87 | 16 |
| Furosemide | Furosemide | 79 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 38 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 76 | 21 |
| Candesartan Cilexetil | Candesartan Cilexetil | 74 | 22 |
| Baclofen | Baclofen | 70 | 43 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 68 | 55 |
| Pentoxifylline | Pentoxifylline | 65 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 27 |
| Atenolol | Atenolol | 64 | 21 |
| Fenofibrate | Fenofibrate | 63 | 24 |
| Nabumetone | Nabumetone | 63 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 62 | 49 |
| Donepezil Hcl | Donepezil Hcl | 60 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | 27 |
| Meclizine Hcl | Meclizine Hcl | 55 | 35 |
| Pregabalin | Pregabalin | 55 | 12 |
| Naproxen | Naproxen | 53 | 26 |
| Humulin N | Insulin Nph Human Isophane | 51 | suppressed |
| Jardiance | Empagliflozin | 51 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 31 |
| Eliquis | Apixaban | 46 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 12 |
| Ibuprofen | Ibuprofen | 42 | 34 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Estazolam | Estazolam | 41 | suppressed |
| Fluconazole | Fluconazole | 41 | 30 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Risperidone | Risperidone | 41 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | 14 |
| Folic Acid | Folic Acid | 40 | 14 |
| Glipizide Er | Glipizide | 40 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 12 |
| Carvedilol | Carvedilol | 39 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 34 |
| Ozempic | Semaglutide | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 13 |
| Finasteride | Finasteride | 37 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 15 |
| Tramadol Hcl | Tramadol Hcl | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 13 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Lumigan | Bimatoprost | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | 14 |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | 15 |
| Bupropion Xl | Bupropion Hcl | 31 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | 11 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Benzonatate | Benzonatate | 30 | 26 |
| Cilostazol | Cilostazol | 30 | suppressed |
| Humulin R | Insulin Regular, Human | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | 11 |
| Ramipril | Ramipril | 30 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 29 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 26 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 24 | 15 |
| Valsartan | Valsartan | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 14 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 22 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 22 | 11 |
| Latanoprost | Latanoprost | 22 | 11 |
| Prednisone | Prednisone | 22 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 21 | suppressed |
| Levo-T | Levothyroxine Sodium | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Tradjenta | Linagliptin | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | 13 |
| Humalog | Insulin Lispro | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 14 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Cymbalta | Duloxetine Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $290.49 · 11 records | BioCryst US Sales Co., LLC | ORLADEYO, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error